Akero Therapeutics downgraded to Hold from Buy at Clear Street

Clear Street downgraded Akero Therapeutics (AKRO) to Hold from Buy with a price target of $54, up from $49, following Novo Nordisk’s (NVO) plan to acquire Akero for $4.7B upfront, equivalent to about $54 per share.